Home Multicentre comparison of free thyroid hormones immunoassays: the Immunocheck study
Article
Licensed
Unlicensed Requires Authentication

Multicentre comparison of free thyroid hormones immunoassays: the Immunocheck study

  • Stefania Giovannini , Gian Carlo Zucchelli , Giorgio Iervasi , Annalisa Iervasi , Maria Rosa Chiesa , Antonella Mercuri , Andrea Renieri , Concetta Prontera , Raffaele Conte and Aldo Clerico EMAIL logo
Published/Copyright: June 17, 2011

Abstract

Background: In order to evaluate whether there is still present a very large variability in measured values and analytical performance among different free thyroid (FT) hormone immunoassays, we considered the results derived from an External Quality Assessment (EQA) scheme, named Immunocheck.

Methods: The EQA Immonocheck study enrolled about 1000 participant laboratories, which measured the 54 quality control samples distributed in the three annual cycles (2007, 2008 and 2009). Participant laboratories produced a total of 30,476 results for FT3 and 31,351 for FT4, respectively.

Results: The results recovered during the EQA cycles allowed the estimation of assay imprecision (i.e., within-method and between-laboratories variability). On average, control samples with lower free triiodothyronine (FT3) and free thyroxine (FT4) concentrations showed higher imprecision values (CV%) than those with levels within or above the normal range. The agreement among the results produced by different methods was estimated by computing the percent differences (i.e., percent bias values) between the concentrations measured by the methods and the mean of all collected results (i.e., consensus mean).

Conclusions: The results of our study demonstrate that a large variability in measured values is still present among different free thyroid hormone immunoassays. Indeed, some immunoassays for both FT3 and FT4 measurement showed percent bias values compared to the consensus mean >20%. Laboratories should inform the clinicians about analytical performance and reference limits of the method used. Furthermore, the clinicians should avoid the use of different methods in the follow-up of patients.


Corresponding author: Prof. Aldo Clerico, MD, Laboratory of Cardiovascular Endocrinology and Cell Biology, Fondazione Toscana G. Monasterio, Via Trieste 41, 56126 Pisa, Italy Phone: +39-0585-493569, Fax: +39-0585-493601

Received: 2011-3-21
Accepted: 2011-5-11
Published Online: 2011-06-17
Published in Print: 2011-10-01

©2011 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Editorial
  2. Laboratory medicine: an essential partner in the care of cancer patients
  3. Reviews
  4. Circulating tumor cells as emerging tumor biomarkers in breast cancer
  5. Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer
  6. Increased plasma concentrations of tumour markers in the absence of neoplasia
  7. Recent progress and clinical importance on pharmacogenetics in cancer therapy
  8. Genetics and Molecular Diagnostics
  9. Genotyping of the hemochromatosis HFE p.H63D and p.C282Y mutations by high-resolution melting with the Rotor-Gene 6000® instrument
  10. General Clinical Chemistry and Laboratory Medicine
  11. Mapping point-of-care performance using locally-smoothed median and maximum absolute difference curves
  12. The use of inflammatory markers as a method for discharging patients post hip or knee arthroplasty
  13. Significant elevation of plasma pentraxin 3 in patients with pelvic inflammatory disease
  14. Combined effects of coffee consumption and serum γ-glutamyltransferase on serum C-reactive protein in middle-aged and elderly Japanese men and women
  15. Multicentre comparison of free thyroid hormones immunoassays: the Immunocheck study
  16. Comparative evaluation of capillary zone electrophoresis and HPLC in the determination of carbohydrate-deficient transferrin
  17. Determinants of blood levels of some thrombogenic biomarkers in healthy Arab adolescent subjects
  18. Analytical performance of a multiplexed, bead-based cytokine detection system in small volume samples
  19. Diagnostic utility of a soluble cytokeratin 18 assay for gastrointestinal graft-vs.-host disease detection
  20. Cancer Diagnostics
  21. The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer
  22. Differential expression of CDC25 phosphatases splice variants in human breast cancer cells
  23. Serum APRIL, a potential tumor marker in pancreatic cancer
  24. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma
  25. Infectious Diseases
  26. New serum biomarkers for detection of tuberculosis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry
  27. Cardiovascular Diseases
  28. Association of a functional polymorphism in the MMP7 gene promoter with susceptibility to vulnerable carotid plaque in a Han Chinese Population
  29. Diabetes
  30. Glycated albumin may be a possible alternative to hemoglobin A1c in diabetic patients with anemia
  31. A simple micro-photometric method for urinary iodine determination
  32. Letters to the Editor
  33. Clinically needed sensitivity for very low levels of Factor XIII: not yet proven for a new functional assay
  34. Apolipoprotein A5-12238 T>C gene polymorphism and risk factors for metabolic syndrome in the Guo Shan Yao and the Han populations
  35. Congress Abstracts
  36. 10.1515/CCLM.2011.738
  37. 1st National Congress of Laboratory Medicine
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.647/html
Scroll to top button